BASF completes acquisition of Becker Underwood
New global business unit Functional Crop Care established
BASF has completed the acquisition of Becker Underwood from Norwest Equity Partners, a U.S.-based private equity investment company, for a purchase price of US$1.02 billion (€785 million). With the acquisition, BASF is now a leading global provider of technologies for biological seed treatment as well as seed treatment colorants and polymers. BASF has also expanded its product portfolio in the areas of biological crop protection, turf and horticulture, animal nutrition and landscape colorants and coatings.
In the coming months, a detailed integration plan will be developed by a joint team of BASF and Becker Underwood employees. Most businesses of Becker Underwood will join the newly established global business unit Functional Crop Care as part of BASF’s Crop Protection division. Within this new unit, BASF will merge its existing research, development and marketing activities in the areas of seed treatment, biological crop protection, plant health, as well as water and resource management with those of Becker Underwood. Becker Underwood’s animal nutrition business will be integrated into BASF’s Nutrition & Health division.
The newly formed global Functional Crop Care unit will become effective January 1, 2013. It will be headed by Dr. Juergen Huff, Senior Vice President.
Dr. Peter Innes, currently CEO of Becker Underwood, has accepted the position of Global Senior Advisor to the Crop Protection division. He will support the integration of Becker Underwood into BASF and the implementation of the Functional Crop Care unit.
In 2011, BASF’s Crop Protection division reported sales of around €4.2 billion and is expecting another record year in 2012. With its products and services, BASF helps growers to improve their yields and the quality of their products.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Ethnopsychopharmacology
MBL scientists find genes linked to human neurological disorders in sea lamprey genome - Discovery will accelerate research on Alzheimer's disease, Parkinson's disease and spinal cord injury

AATec Medical reports significant progress in company’s first year towards unlocking the therapeutic potential of AAT - Major advancements in the development of ATL-105 for the treatment of inflammatory lung diseases
Intersection between nervous and musculoskeletal system could be key to treating Pompe disease
Evolva reaches milestone in BASF collaboration

Microchip detects vaccination gaps - A new microchip tests for antibodies against corona, measles, diphtheria and tetanus in parallel - with a single drop of blood

15 emerging technologies that could reduce global catastrophic biological risks
Rambutan

Seeing inside cells with an integrated nanowire probe - Real-time, in-situ sensing and tracking of cell development and maturation is achieved using a label-free nano-optical device
Deciphering how CD4 T cells die during HIV infection
